US20210361559A1 - Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis - Google Patents
Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis Download PDFInfo
- Publication number
- US20210361559A1 US20210361559A1 US16/496,565 US201816496565A US2021361559A1 US 20210361559 A1 US20210361559 A1 US 20210361559A1 US 201816496565 A US201816496565 A US 201816496565A US 2021361559 A1 US2021361559 A1 US 2021361559A1
- Authority
- US
- United States
- Prior art keywords
- composition
- cirsium japonicum
- extract
- japonicum extract
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000729173 Cirsium japonicum Species 0.000 title claims abstract description 97
- 239000000284 extract Substances 0.000 title claims abstract description 97
- 239000000203 mixture Substances 0.000 title claims abstract description 76
- 230000004936 stimulating effect Effects 0.000 title claims abstract description 24
- 230000003061 melanogenesis Effects 0.000 title claims abstract description 22
- 239000004480 active ingredient Substances 0.000 title description 27
- 210000004209 hair Anatomy 0.000 claims abstract description 39
- 206010047642 Vitiligo Diseases 0.000 claims abstract description 36
- 239000002537 cosmetic Substances 0.000 claims abstract description 27
- 208000003367 Hypopigmentation Diseases 0.000 claims abstract description 21
- 230000003793 hair pigmentation Effects 0.000 claims abstract description 21
- 230000003425 hypopigmentation Effects 0.000 claims abstract description 21
- 239000004615 ingredient Substances 0.000 claims abstract description 12
- 238000009472 formulation Methods 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 9
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 21
- 206010040880 Skin irritation Diseases 0.000 abstract description 7
- 230000003013 cytotoxicity Effects 0.000 abstract description 7
- 231100000135 cytotoxicity Toxicity 0.000 abstract description 7
- 230000036556 skin irritation Effects 0.000 abstract description 7
- 231100000475 skin irritation Toxicity 0.000 abstract description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- 210000004027 cell Anatomy 0.000 description 24
- 230000008099 melanin synthesis Effects 0.000 description 22
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 21
- 210000003491 skin Anatomy 0.000 description 18
- 210000002752 melanocyte Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- 230000001737 promoting effect Effects 0.000 description 14
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000002609 medium Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000000605 extraction Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- -1 glycerol aliphatic ester Chemical class 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000049 pigment Substances 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 7
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 230000002335 preservative effect Effects 0.000 description 6
- 239000008213 purified water Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 229940057995 liquid paraffin Drugs 0.000 description 5
- 238000002137 ultrasound extraction Methods 0.000 description 5
- 241000132536 Cirsium Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 235000013871 bee wax Nutrition 0.000 description 4
- 239000012166 beeswax Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 235000015112 vegetable and seed oil Nutrition 0.000 description 4
- 239000008158 vegetable oil Substances 0.000 description 4
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000001382 Experimental Melanoma Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 3
- 229940032094 squalane Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 239000007963 capsule composition Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 244000167125 Cinnamomum japonicum Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000213810 Ephelis Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 240000000604 Lespedeza bicolor Species 0.000 description 1
- 235000016677 Lespedeza bicolor Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241001480064 Quercus variabilis Species 0.000 description 1
- 241000228577 Rhododendron schlippenbachii Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000035614 depigmentation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000002758 humerus Anatomy 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000020854 vein disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/04—Preparations for care of the skin for chemically tanning the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
Definitions
- the present invention relates to a composition for stimulating melanogenesis comprising Cirsium japonicum extracts as active ingredient, more particularly, which promote melanin production, induce blackening, and can treat, improve, or prevent vitiligo, gray hair, or hypochromatism.
- Melanin produced in melanin cell (melanocyte) existing in the epidermal basal layer of human skin refers to a phenolic polymer having complex form of black pigment and protein. Such melanin determines human skin color by its concentration and distribution and plays the role of protecting human skin from UV rays.
- melanin is excessively produced, it causes pigmentation such as freckle, ephelis, etc.
- melanin production is excessively suppressed, it may lead to skin disease of vitiligo, gray hair by a decrease of number and function in melanocyte, or hypochromatin which can be risk factor for skin cancer. Therefore, as much as whitening related study of suppressing melanin production, study of inducing blackening by stimulating melanogenesis is also very important.
- Korean Patent Registration No. No. 10-1669359 disclose a composition for stimulating melanin synthesis containing mixture of Rhododendron schlippenbachii extract, Lespedeza bicolor extract and Quercus variabilis extract, but the above composition has the problem of complex raw material preparation and manufacturing process since it mixes and uses several extracts.
- Cirsium japonicum is perennial belonging to compositae which is widely used for private and Korean medicine prescription, and young sprouts are used for food.
- Generic name of Cirsium japonicum, Cirsium is from Greek word meaning vein cure, and it originated from the use as drug curing disease of vein inflating from ancient times.
- Cirsium japonicum contains various secondary metabolites with excellent physiological activity such as apigenin, myricetin, luteolin and kaempferol, and it is known to have effect for hydrolymph, hemostasis, extravasated blood removal, boil cure, etc.
- Korean Patent Registration No. 10-1281710 discloses obesity treatment and prevention effect of Cirsium japonicum extract
- Korean Patent Publication No. 10-2017-0025375 discloses skin regeneration, skin wrinkle improvement, skin whitening effect, etc. of Cirsium japonicum extract, but it is not yet disclosing the melanin synthesis acceleration effect of Cirsium japonicum extract.
- the present inventors have made extensive efforts to develop natural material, which is harmless to the human body and has excellent effect to stimulate melanocytes, to fundamentally solve vitiligo, gray hair and hypochromatin, As a result, the present inventors have found that a composition comprising Cirsium japonicum extract induces blackening by stimulating melanocytes and is excellent in the human body stability without skin irritation and cell toxicity, and then have completed the present invention.
- the present invention provides a cosmetic composition for preventing or improving vitiligo, gray hair or hypochromatism, comprising Cirsium japonicum extract as active ingredient.
- the present invention provides a pharmaceutical composition, for preventing or treating vitiligo, gray hair or hypochromatism comprising Cirsium japonicum extract as active ingredient.
- the present invention provides a food composition for preventing or improving vitiligo, gray hair or hypochromatism, comprising Cirsium japonicum extract as active ingredient.
- the present invention provides a method of preventing, improving or treating vitiligo, gray hair or hypochromatism of a subject by administering said composition comprising Cirsium japonicum extract as active ingredient to the subject and by stimulating melanogenesis of the subject.
- Cirsium japonicum is perennial belonging to compositae which is widely used for private and Korean medicine prescription, and its young sprout are used for food.
- Cirsium japonicum extract means that is extracted from any one or more selected from the group consisting of flowers, leaves, stems, roots and whole plant of Cirsium japonicum , and preferably means that is extracted from flowers of Cirsium japonicum.
- Cirsium japonicum extract according to the present invention promotes the production of melanocyte, which is a pigment cell, and increases the synthesis of melanin by activating the produced melanocytes, resulting in repigmentation.
- the Cirsium japonicum extract of the present invention can be extracted solvent known in the art and the extracted liquid can be used in liquid form or concentrated and/or dried form.
- the solvent may be an extraction solvent selected from water, an anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol and the like), a mixed solvent of the lower alcohol with water, acetone, ethyl acetate, chloroform or 1,3-butylene glycol.
- the solvent may be an extraction solvent selected from methanol, ethanol, or butanol.
- the present invention is not limited thereto, and since the extraction degree and loss degree of the active ingredient of the extract may vary depending on the organic solvent to be extracted, it is preferable to select and use an appropriate organic solvent.
- Examples of the extraction method include, but are not limited to, cooling immersion extraction method, ultrasonic extraction method, or reflux cooling extraction method, and the like. It is preferable to carry out by the ultrasonic extraction method.
- ultrasonic extraction is a method of extracting useful components from various natural materials at room temperature with physical force, not chemical force, using vibrating element with 20,000 or more vibrations per second.
- ultrasonic extraction has the advantage of being able to extract at a high concentration without destroying the active components contained in the natural material at room temperature.
- the ultrasonic extraction may be performed for 24 to 72 hours at room temperature for the dried Cirsium japonicum powder in 60 to 80% ethanol solution. Preferably, it is carried out for 36 to 60 hours at room temperature in 65% to 75% ethanol solution. More preferably, it is carried out for 48 hours at room temperature in 70% ethanol solution. If the value is below the above lower limit, the active components contained in Cirsium japonicum is not sufficiently extracted. If the upper limit is exceeded, there is no significant difference in the extraction amount of the active components, and impurities other than the active components are extracted and the efficiency of the process is reduced.
- the unripe Cirsium japonicum extract of the present invention comprises all extracts, fractions and refinings obtained from the respective steps of extraction, fractionation or purification.
- the Cirsium japonicum extract of the present invention is comprised in the composition of the present invention in an amount of 0.0001 to 70.0% by weight, preferably 0.001 to 68.0% by weight relative to the weight of total composition.
- weight of the Cirsium japonicum extract is less than 0.0001% by weight, it cannot be expected to promote the melanin production, and when it is greater than 70% by weight, an increase of the effect according to the increase of the content of the Cirsium japonicum extract is very weak and there is a problem in preparing a pharmaceutical formulation.
- the composition for stimulating melanogenesis comprising the Cirsium japonicum extract of the present invention as an active ingredient may be used a cosmetic composition or a pharmaceutical composition for the prevention, improvement or treatment of vitiligo, white hair or hypopigmentation caused by the destruction or dysfunction of melanocytes.
- the vitiligo is a phenomenon in which melanocytes are destroyed by abnormalities of autoimmune function and white spots of various sizes and shapes appear on the skin, and it refers to acquired depigmentation disease.
- the gray hair refers to a phenomenon in which the hair turns white while the number and functionality of melanocytes in hair root decrease.
- hypochromatism refers to a disease in which local melanocytes are functional disorder due to skin diseases such as eczema, atopic dermatitis, and inflammatory dermatitis, and the skin at the lesion site becomes white temporarily.
- the prevention, improvement or treatment of vitiligo, gray hair or hypochromatism stimulates inactive melanocytes or pigmented hair cells present in the skin or hair follicle to promote differentiation, proliferation and migration of these cells, and produce melanin.
- the symptoms of vitiligo, gray hair or hypochromatism are prevented, improved or treated.
- the present invention provides a cosmetic composition that is effective in the prevention or improvement of vitiligo, white hair or hypopigmentation by promoting the production of melanin in the cell by including Cirsium japonicum extract as an active ingredient.
- the Cirsium japonicum extract of the present invention is comprised in the cosmetic composition of the present invention in an amount of 0.0001 to 15.0% by weight, preferably 0.001 to 10.0% by weight relative to the weight of total composition.
- weight of the Cirsium japonicum extract is less than 0.0001% by weight, it cannot be expected to prevent or improve vitiligo, white hair or hypopigmentation, and when it is greater than 15% by weight, there is a problem in preparing a cosmetic formulation.
- the cosmetic composition of the present invention may further contain, in addition to Cirsium japonicum extract as an effective ingredient, components that are conventionally used in cosmetic compositions.
- components include conventional auxiliaries, such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers.
- the cosmetic composition may be prepared in any formulation commonly prepared in the art. For example, it may be formulated as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powdered foundation, an emulsion foundation, a wax foundation, a spray, or the like. More specifically, the cosmetic composition may be formulated into a nutrient cream, a lotion astringent, a softening toner, a lotion, an essence, a nutrient gel, or massage cream, or the like. But it is not particularly limited there to.
- the formulation of the cosmetic composition is the paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. can be used as the carrier ingredient.
- the lactose, talc, silica, aluminum hydroxide, fig ⁇ calcium silicate or polyamide powder can be utilized, and in particular when it is the spray, a propellant such as chlorofluorohydrocarbon, propane/butane or dimethyl ether can be additionally included.
- the solvent, solubilizing agent or emulsifying agent can be utilized as a carrier ingredient.
- a carrier ingredient For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-buthylglycol oil, glycerol aliphatic ester, polyethylene glycol or aliphatic ester of sorbitan, etc. can be utilized as the carrier ingredient.
- the liquid diluents such as water, ethanol or propylene glycol, suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacant, etc. can be utilized as the carrier ingredient.
- the aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulphosuccinic monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanoline derivative or ethoxylated glycerol fatty acid ester, etc. can be utilized as the carrier ingredient.
- the present invention provides a pharmaceutical composition that is effective in the prevention or treatment of vitiligo, white hair or hypopigmentation by promoting the production of melanin in the cell by including Cirsium japonicum extract as an active ingredient.
- the Cirsium japonicum extract of the present invention is comprised in the pharmaceutical composition of the present invention in an amount of 0.0001 to 70.0% by weight, preferably 0.001 to 68.0% by weight relative to the weight of total composition.
- weight of the Cirsium japonicum extract is less than 0.0001% by weight, it cannot be expected to prevent or treat vitiligo, white hair or hypopigmentation, and when it is greater than 70.0% by weight, there is a problem in preparing a pharmaceutical formulation.
- the pharmaceutical composition may further contain, in addition to Cirsium japonicum extract as an effective ingredient, a carrier that is conventionally acceptable in the pharmaceutical composition.
- the carrier suitable for the pharmaceutical composition is the carrier commonly used in the formulation.
- the carrier includes, but not limited to, carbohydrate compounds (e.g. lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose etc.), acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, celloluse, water, syrup, salt solution, alcohol, gum Arabic, vegetable oils (e.g. corn oil, cotton seed oil, soy milk, olive oil. Coconut oil), polyethylene glycol, methyl cellulose, methylhydroxy benzoate, prophylhydroxy benzoate, talc, magnesium stearate, mineral oil, and the like.
- carbohydrate compounds e.g. lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose etc.
- acacia gum e.g. lacto
- the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like.
- the pharmaceutical composition of the present invention can be administered orally or parenterally to mammals such as rats, mice, livestock, humans, etc. and can be applied, preferably, by parenteral administration, more preferably in the manner of topical application by application.
- the effective dose level of the pharmaceutical composition can be variously determined by the method of formulation, mode of administration, age, weight, health and sex of a patient, food, time of administration, route of administration, rate of excretion and sensitivity of the patient to the drug and the like.
- Oral dosages of the pharmaceutical compositions of the present invention are in the range of 0.001-300 mg/kg (body weight) on an adult basis.
- the dosage does not limit the scope of the present invention.
- the cosmetic or pharmaceutical composition comprising the Cirsium japonicum extract of the present invention as an active ingredient stimulating melanogenesis of the subject by administration, such as administration in the subject, subcutaneous administration or topical application by application to a subject, and melanin synthesis is increased by activation of the resulting melanocytes and then the pigment re-deposition (repigmentation) is occurred. Therefore, the cosmetic or pharmaceutical composition has an advantage that can achieve the purpose of alleviating, getting better, preventing, improving or treating vitiligo, white hair or hypopigmentation.
- the present invention provides a method and use thereof for improving vitiligo, white hair and hypopigmentation of a subject by administering to the subject a composition for stimulating melanogenesis comprising Cirsium japonicum extract as an active ingredient.
- composition administered to the subject has an effect of improving or treating vitiligo, white hair and hypopigmentation of the subject due to the melanin production promoting effect as described above.
- subject in the present invention means a mammal such as monkey, cow, horse, pig, sheep, dog, cat, rat, mouse, chimpanzee, etc., including human, having the disease symptom of which can be alleviated by administering the composition of the present invention.
- the term “improvement” means (a) inhibition of a development, (b) alleviation and (c) removal of the vitiligo, white hair and hypopigmentation resulting from disruption or dysfunction of melanocytes in a subject.
- Cirsium japonicum extract of the present invention is a natural extract that has no skin irritation and cytotoxicity and excellent human stability and has almost no side effects on the human body, and thus is very effective in stimulating melanogenesis. It can be safely used as an active ingredient in therapeutic cosmetics or pharmaceutical compositions.
- the present invention provides a method for preventing, improving, or treating vitiligo, white hair or hypopigmentation by promoting the production of melanin by administering to a subject a composition comprising the Cirsium japonicum extract as an active ingredient.
- the subject is a mammal, including humans, which is intended to improve vitiligo, white hair or hypopigmentation by stimulating melanogenesis.
- the administration is oral or parenteral administration, preferably parenteral administration, more preferably topical administration by application.
- the dosage and the like can be easily changed and used by those skilled in the art the method of formulation, mode of administration, age, weight, sex of a patient, morbidity, etc.
- the melanin production of the subject may be promoted to prevent and improve vitiligo, white hair or hypopigmentation.
- the composition for stimulating melanogenesis comprising Cirsium japonicum extract as an effective ingredient has no skin irritation and cytotoxicity and is excellent in human stability and very effective in stimulating melanogenesis. Therefore, the composition can be safely used in cosmetic or pharmaceutical composition for preventing, improving or treating vitiligo, white hair or hypopigmentation.
- FIG. 1 shows the melanin synthesis promoting effect depending on the concentration of Cirsium japonicum extract in human melanocyte.
- FIG. 2 shows the melanin synthesis promoting effect depending on the concentration of Cirsium japonicum extract in B16 melanoma cell.
- FIG. 3 shows the melanin synthesis promoting effect depending on the concentration of Cirsium japonicum extract in 3D skin.
- the present invention provides a composition for stimulating melanogenesis comprising Cirsium japonicum extract as an active ingredient.
- the present invention provides a cosmetic composition for preventing or improving vitiligo, white hair or hypopigmentation, characterized in that it comprises Cirsium japonicum extract as an active ingredient.
- the present invention provides a pharmaceutical composition for preventing or treating vitiligo, white hair or hypopigmentation, characterized in that it comprises Cirsium japonicum extract as an active ingredient.
- the present invention provides a method for preventing, improving or treating vitiligo, white hair or hypopigmentation by promoting the melanin production by administering to the subject a composition comprising the Cirsium japonicum extract as an active ingredient.
- Cirsium japonicum flowers were harvested and washed thoroughly to remove any foreign matter and impurities. It was dried at 20 to 35° C. and then ground to a particle size of 1 mm or less. Thereafter, 1 kg of the Cirsium japonicum flower powder was soaked in 70% ethanol solvent, sonicated for 48 hours, and the obtained extract was filtered using filter paper (Advantes, No. 2). The filtrate was concentrated under reduced pressure to prepare Cirsium japonicum extract.
- Human melanocytes were inoculated into 6-well plate containing M254 medium with HMGS (Human Melanocytes Growth Supplement) at a density 1.5 ⁇ 10 5 cells per well, and then cultured in 5% concentration of CO 2 cultivator under the condition of 37° C. until at least about 80% adhered to the bottom of the well. Thereafter, the medium was removed and the sample of Example 1 was replaced with a medium diluted to an appropriate concentration, and then incubated in 5% concentration of CO 2 under the condition of 37° C. for 5 days.
- the concentration range of Cirsium japonicum extract according to Example 1 was determined to be 1 ppm, 3 ppm, 5 ppm without cytotoxicity.
- the cells from which the medium was removed were washed with PBS (phosphated buffer saline), and the cells were obtained.
- the obtained cells were counted using a hemocytometer and then centrifuged at 10,000 to 13,000 rpm for 10 minutes to remove the supernatant and pellets were obtained.
- the obtained cell pellet was dried at 60° C., and then 100 ⁇ l of 1M sodium hydroxide solution containing 10% DMSO was added to obtain an intracellular melanin solution in a 60° C. thermostat. Using this solution, the absorbance at 450 nm was measured with a microplate reader to determine the amount of melanin per cell. The results are shown in Table 1 and FIG. 1 .
- Cirsium japonicum extract according to the present invention was observed to increase the rate of melanin production in a concentration-dependent compared to the control. Therefore, Cirsium japonicum extract according to the present invention was found to have the effect of promoting the production of melanin.
- B16 melanoma cells were inoculated into 6-well plate containing DMEM medium with 10% FBS (Fetal Bovine Serum) at a density 1.5 ⁇ 10 5 cells per well, and then cultured in 5% concentration of CO 2 cultivator under the condition of 37° C. until at least about 80% adhered to the bottom of the well. Thereafter, the medium was removed and the sample of Example 1 was replaced with a medium diluted to an appropriate concentration, and then incubated in 5% concentration of CO 2 under the condition of 37° C. for 3 days.
- the concentration range of Cirsium japonicum extract according to Example 1 was determined to be 10 ppm, 50 ppm, 100 ppm without cytotoxicity.
- the cells from which the medium was removed were washed with PBS (phosphated buffer saline), and the cells were obtained.
- the obtained cells were counted using a hemocytometer and then centrifuged at 10,000 to 13,000 rpm for 10 minutes to remove the supernatant and pellets were obtained.
- the obtained cell pellet was dried at 60° C., and then 100 ⁇ l of 1M sodium hydroxide solution containing 10% DMSO was added to obtain an intracellular melanin solution in a 60° C. thermostat. Using this solution, the absorbance at 450 nm was measured with a microplate reader to determine the amount of melanin per cell. The results are shown in Table 2 and FIG. 2 .
- Cirsium japonicum extract according to the present invention was observed to increase the rate of melanin production in a concentration-dependent compared to the control.
- Cirsium japonicum extract was treated with 100 ppm, it was observed that the melanin production was promoted more than two times compared to the control. Therefore, Cirsium japonicum extract according to the present invention was found to have the effect of promoting the production of melanin.
- 3D skin were inoculated into 6-well plate containing maintenance medium, and then cultured in 5% concentration of CO 2 cultivator under the condition of 37° C. Thereafter, the medium was removed, and the Cirsium japonicum extracts were treated at ppm and 100 ppm without cytotoxicity. Cirsium japonicum extract was replaced three times with a concentration-treated medium for 10 days and then incubated at 5% CO 2 and 37° C. The cells from which the medium was removed were washed with PBS (phosphated buffer saline), and the cells were obtained. The obtained cells were centrifuged at 10,000 to 13,000 rpm for 10 minutes to remove the supernatant and pellets were obtained.
- PBS phosphated buffer saline
- the obtained cell pellet was dried at 60° C., and then 100 ⁇ l of 1M sodium hydroxide solution containing 10% DMSO was added to obtain an intracellular melanin solution in a 60° C. thermostat. Using this solution, the absorbance at 450 nm was measured with a microplate reader to determine the amount of melanin per cell. The results are shown in Table 3 and FIG. 3 .
- Cirsium japonicum extract according to the present invention was observed to increase the rate of melanin production in a concentration-dependent compared to the control. Therefore, Cirsium japonicum extract according to the present invention was found to have the effect of promoting the production of melanin.
- Example 5 Test for Identifying the Safety of Cirsium japonicum Extract to the Human Skin
- Cirsium japonicum extract In order to identify as to whether the Cirsium japonicum extract is safe or not, a test for identifying the safety to the human skin was performed. For this, a cumulative skin irritation was carried out.
- the nourishing cream prepared as described above was applied as a patch to areas of humerus of 30 adults for accumulated 24 hours on alternate day in total 9 times to test as to whether the Cirsium japonicum extract stimulates the skin.
- Mean reaction degree [ ⁇ (reaction index ⁇ reaction degree)/(total number of the subject ⁇ the highest score (four point)) ⁇ 100]/times of the test (9 times) [Experimental Formula 1]
- test group are all less than 3, and thus, it was determined that the Cirsium japonicum extract is safe for use on human skin which does not show clear cumulative skin irritation.
- composition of the present invention may be prepared as an example as follows but is not limited thereto.
- a nourishing cream containing the Cirsium japonicum extract as an active ingredient was prepared according to a conventional method.
- Cirsium japonicum extract 100 Corn starch 100 Lactose 100 Magnesium stearate 2
- Cirsium japonicum extract 100 Corn starch 100 Lactose 100 Magnesium stearate 2
- the composition for stimulating melanogenesis comprising Cirsium japonicum extract as an effective ingredient has no skin irritation and cytotoxicity and is excellent in human stability and very effective in stimulating melanogenesis. Therefore, the composition can be safely used in cosmetic or pharmaceutical composition for preventing, improving or treating vitiligo, white hair or hypopigmentation.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- The present invention relates to a composition for stimulating melanogenesis comprising Cirsium japonicum extracts as active ingredient, more particularly, which promote melanin production, induce blackening, and can treat, improve, or prevent vitiligo, gray hair, or hypochromatism.
- Melanin produced in melanin cell (melanocyte) existing in the epidermal basal layer of human skin refers to a phenolic polymer having complex form of black pigment and protein. Such melanin determines human skin color by its concentration and distribution and plays the role of protecting human skin from UV rays.
- If melanin is excessively produced, it causes pigmentation such as freckle, ephelis, etc. On the contrary, if melanin production is excessively suppressed, it may lead to skin disease of vitiligo, gray hair by a decrease of number and function in melanocyte, or hypochromatin which can be risk factor for skin cancer. Therefore, as much as whitening related study of suppressing melanin production, study of inducing blackening by stimulating melanogenesis is also very important.
- These vitiligo, gray hair and hypochromatism do not only look good outside but also cause many difficulties in social activities. Thus, for vitiligo and hypochromatism, there are many cases of treatment using surgical procedure or temporarily hiding with external skin applications such as cosmetics, and for gray hair, many people try to temporarily hide the gray hair with dyeing. However, since such methods are not their fundamental methods of prevention, improvement or treatment, it is necessary to study melanin production accelerator for more fundamental solution.
- With this regard, Korean Patent Registration No. No. 10-1669359 disclose a composition for stimulating melanin synthesis containing mixture of Rhododendron schlippenbachii extract, Lespedeza bicolor extract and Quercus variabilis extract, but the above composition has the problem of complex raw material preparation and manufacturing process since it mixes and uses several extracts.
- On the other hand, Cirsium japonicum is perennial belonging to compositae which is widely used for private and Korean medicine prescription, and young sprouts are used for food. Generic name of Cirsium japonicum, Cirsium, is from Greek word meaning vein cure, and it originated from the use as drug curing disease of vein inflating from ancient times. Cirsium japonicum contains various secondary metabolites with excellent physiological activity such as apigenin, myricetin, luteolin and kaempferol, and it is known to have effect for hydrolymph, hemostasis, extravasated blood removal, boil cure, etc.
- With regard to the efficacy of the above Cirsium japonicum, Korean Patent Registration No. 10-1281710 discloses obesity treatment and prevention effect of Cirsium japonicum extract, and Korean Patent Publication No. 10-2017-0025375 discloses skin regeneration, skin wrinkle improvement, skin whitening effect, etc. of Cirsium japonicum extract, but it is not yet disclosing the melanin synthesis acceleration effect of Cirsium japonicum extract.
- Accordingly, the present inventors have made extensive efforts to develop natural material, which is harmless to the human body and has excellent effect to stimulate melanocytes, to fundamentally solve vitiligo, gray hair and hypochromatin, As a result, the present inventors have found that a composition comprising Cirsium japonicum extract induces blackening by stimulating melanocytes and is excellent in the human body stability without skin irritation and cell toxicity, and then have completed the present invention.
- It is an object of the present invention to provide a composition for stimulating melanogenesis.
- It is another object of the present invention to provide a cosmetic composition for preventing or improving vitiligo, gray hair or hypochromatism comprising the above melanogenesis stimulating composition.
- It is still another object of the present invention to provide a pharmaceutical composition for preventing or treating vitiligo, gray hair or hypochromatism comprising the above melanogenesis stimulating composition.
- It is still another object of the present invention to provide a food composition for preventing or improving vitiligo, gray hair or hypochromatism comprising the above melanogenesis stimulating composition.
- In order to achieve the above objectives, the present invention provides composition for stimulating melanogenesis comprising Cirsium japonicum extract as an active ingredient.
- In order to achieve another above objective, the present invention provides a cosmetic composition for preventing or improving vitiligo, gray hair or hypochromatism, comprising Cirsium japonicum extract as active ingredient.
- In order to achieve still another above objective, the present invention provides a pharmaceutical composition, for preventing or treating vitiligo, gray hair or hypochromatism comprising Cirsium japonicum extract as active ingredient.
- In order to achieve still another above objective, the present invention provides a food composition for preventing or improving vitiligo, gray hair or hypochromatism, comprising Cirsium japonicum extract as active ingredient.
- In order to achieve still another above objective, the present invention provides a method of preventing, improving or treating vitiligo, gray hair or hypochromatism of a subject by administering said composition comprising Cirsium japonicum extract as active ingredient to the subject and by stimulating melanogenesis of the subject.
- In the present invention, Cirsium japonicum is perennial belonging to compositae which is widely used for private and Korean medicine prescription, and its young sprout are used for food.
- In the present invention, Cirsium japonicum extract means that is extracted from any one or more selected from the group consisting of flowers, leaves, stems, roots and whole plant of Cirsium japonicum, and preferably means that is extracted from flowers of Cirsium japonicum.
- The Cirsium japonicum extract according to the present invention promotes the production of melanocyte, which is a pigment cell, and increases the synthesis of melanin by activating the produced melanocytes, resulting in repigmentation.
- The Cirsium japonicum extract of the present invention can be extracted solvent known in the art and the extracted liquid can be used in liquid form or concentrated and/or dried form. Herein, the solvent may be an extraction solvent selected from water, an anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol and the like), a mixed solvent of the lower alcohol with water, acetone, ethyl acetate, chloroform or 1,3-butylene glycol. Preferably, the solvent may be an extraction solvent selected from methanol, ethanol, or butanol. However, the present invention is not limited thereto, and since the extraction degree and loss degree of the active ingredient of the extract may vary depending on the organic solvent to be extracted, it is preferable to select and use an appropriate organic solvent.
- Examples of the extraction method include, but are not limited to, cooling immersion extraction method, ultrasonic extraction method, or reflux cooling extraction method, and the like. It is preferable to carry out by the ultrasonic extraction method.
- Above ultrasonic extraction is a method of extracting useful components from various natural materials at room temperature with physical force, not chemical force, using vibrating element with 20,000 or more vibrations per second. Unlike solvent extraction, vegetable oil extraction or water steam distillation extraction, ultrasonic extraction has the advantage of being able to extract at a high concentration without destroying the active components contained in the natural material at room temperature.
- As one specific example, the ultrasonic extraction may be performed for 24 to 72 hours at room temperature for the dried Cirsium japonicum powder in 60 to 80% ethanol solution. Preferably, it is carried out for 36 to 60 hours at room temperature in 65% to 75% ethanol solution. More preferably, it is carried out for 48 hours at room temperature in 70% ethanol solution. If the value is below the above lower limit, the active components contained in Cirsium japonicum is not sufficiently extracted. If the upper limit is exceeded, there is no significant difference in the extraction amount of the active components, and impurities other than the active components are extracted and the efficiency of the process is reduced.
- The unripe Cirsium japonicum extract of the present invention comprises all extracts, fractions and refinings obtained from the respective steps of extraction, fractionation or purification.
- The Cirsium japonicum extract of the present invention is comprised in the composition of the present invention in an amount of 0.0001 to 70.0% by weight, preferably 0.001 to 68.0% by weight relative to the weight of total composition. When the weight of the Cirsium japonicum extract is less than 0.0001% by weight, it cannot be expected to promote the melanin production, and when it is greater than 70% by weight, an increase of the effect according to the increase of the content of the Cirsium japonicum extract is very weak and there is a problem in preparing a pharmaceutical formulation.
- In one specific aspect, the composition for stimulating melanogenesis comprising the Cirsium japonicum extract of the present invention as an active ingredient may be used a cosmetic composition or a pharmaceutical composition for the prevention, improvement or treatment of vitiligo, white hair or hypopigmentation caused by the destruction or dysfunction of melanocytes.
- The vitiligo is a phenomenon in which melanocytes are destroyed by abnormalities of autoimmune function and white spots of various sizes and shapes appear on the skin, and it refers to acquired depigmentation disease.
- The gray hair refers to a phenomenon in which the hair turns white while the number and functionality of melanocytes in hair root decrease.
- Hypochromatism refers to a disease in which local melanocytes are functional disorder due to skin diseases such as eczema, atopic dermatitis, and inflammatory dermatitis, and the skin at the lesion site becomes white temporarily.
- In the present invention, the prevention, improvement or treatment of vitiligo, gray hair or hypochromatism stimulates inactive melanocytes or pigmented hair cells present in the skin or hair follicle to promote differentiation, proliferation and migration of these cells, and produce melanin. Thereby, the symptoms of vitiligo, gray hair or hypochromatism are prevented, improved or treated.
- According to one embodiment of the present invention, the present invention provides a cosmetic composition that is effective in the prevention or improvement of vitiligo, white hair or hypopigmentation by promoting the production of melanin in the cell by including Cirsium japonicum extract as an active ingredient.
- The Cirsium japonicum extract of the present invention is comprised in the cosmetic composition of the present invention in an amount of 0.0001 to 15.0% by weight, preferably 0.001 to 10.0% by weight relative to the weight of total composition. When the weight of the Cirsium japonicum extract is less than 0.0001% by weight, it cannot be expected to prevent or improve vitiligo, white hair or hypopigmentation, and when it is greater than 15% by weight, there is a problem in preparing a cosmetic formulation.
- The cosmetic composition of the present invention may further contain, in addition to Cirsium japonicum extract as an effective ingredient, components that are conventionally used in cosmetic compositions. Examples of the components include conventional auxiliaries, such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers.
- The cosmetic composition may be prepared in any formulation commonly prepared in the art. For example, it may be formulated as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, a surfactant-containing cleanser, an oil, a powdered foundation, an emulsion foundation, a wax foundation, a spray, or the like. More specifically, the cosmetic composition may be formulated into a nutrient cream, a lotion astringent, a softening toner, a lotion, an essence, a nutrient gel, or massage cream, or the like. But it is not particularly limited there to.
- When the formulation of the cosmetic composition is the paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc or zinc oxide, etc. can be used as the carrier ingredient.
- When the formulation of the cosmetic composition is the powder or spray, the lactose, talc, silica, aluminum hydroxide, fig\calcium silicate or polyamide powder can be utilized, and in particular when it is the spray, a propellant such as chlorofluorohydrocarbon, propane/butane or dimethyl ether can be additionally included.
- When the formulation of the cosmetic composition is the solution or turbid fluid, the solvent, solubilizing agent or emulsifying agent can be utilized as a carrier ingredient. For example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-buthylglycol oil, glycerol aliphatic ester, polyethylene glycol or aliphatic ester of sorbitan, etc. can be utilized as the carrier ingredient.
- When the formulation of the cosmetic composition is suspension, the liquid diluents such as water, ethanol or propylene glycol, suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tragacant, etc. can be utilized as the carrier ingredient.
- When the formulation of the cosmetic composition is the surfactant-containing cleansing, the aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulphosuccinic monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, lanoline derivative or ethoxylated glycerol fatty acid ester, etc. can be utilized as the carrier ingredient.
- According to one embodiment of the present invention, the present invention provides a pharmaceutical composition that is effective in the prevention or treatment of vitiligo, white hair or hypopigmentation by promoting the production of melanin in the cell by including Cirsium japonicum extract as an active ingredient.
- The Cirsium japonicum extract of the present invention is comprised in the pharmaceutical composition of the present invention in an amount of 0.0001 to 70.0% by weight, preferably 0.001 to 68.0% by weight relative to the weight of total composition. When the weight of the Cirsium japonicum extract is less than 0.0001% by weight, it cannot be expected to prevent or treat vitiligo, white hair or hypopigmentation, and when it is greater than 70.0% by weight, there is a problem in preparing a pharmaceutical formulation.
- The pharmaceutical composition may further contain, in addition to Cirsium japonicum extract as an effective ingredient, a carrier that is conventionally acceptable in the pharmaceutical composition.
- The carrier suitable for the pharmaceutical composition is the carrier commonly used in the formulation. The carrier includes, but not limited to, carbohydrate compounds (e.g. lactose, amylose, dextrose, sucrose, sorbitol, mannitol, starch, cellulose etc.), acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, celloluse, water, syrup, salt solution, alcohol, gum Arabic, vegetable oils (e.g. corn oil, cotton seed oil, soy milk, olive oil. Coconut oil), polyethylene glycol, methyl cellulose, methylhydroxy benzoate, prophylhydroxy benzoate, talc, magnesium stearate, mineral oil, and the like.
- In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like. The suitable pharmaceutically acceptable carrier or agents are specifically disclosed in, for example, Remington's Pharmaceutical Sciences (19th ed., 1995).
- The pharmaceutical composition of the present invention can be administered orally or parenterally to mammals such as rats, mice, livestock, humans, etc. and can be applied, preferably, by parenteral administration, more preferably in the manner of topical application by application.
- The effective dose level of the pharmaceutical composition can be variously determined by the method of formulation, mode of administration, age, weight, health and sex of a patient, food, time of administration, route of administration, rate of excretion and sensitivity of the patient to the drug and the like. Oral dosages of the pharmaceutical compositions of the present invention are in the range of 0.001-300 mg/kg (body weight) on an adult basis. In addition, in the case of external preparations, it is preferable to apply once to 5 times a day in an amount of 1.0 to 3.0 ml on an adult basis and continue for 1 month or more. However, the dosage does not limit the scope of the present invention.
- The cosmetic or pharmaceutical composition comprising the Cirsium japonicum extract of the present invention as an active ingredient stimulating melanogenesis of the subject by administration, such as administration in the subject, subcutaneous administration or topical application by application to a subject, and melanin synthesis is increased by activation of the resulting melanocytes and then the pigment re-deposition (repigmentation) is occurred. Therefore, the cosmetic or pharmaceutical composition has an advantage that can achieve the purpose of alleviating, getting better, preventing, improving or treating vitiligo, white hair or hypopigmentation.
- In one specific embodiment, the present invention provides a method and use thereof for improving vitiligo, white hair and hypopigmentation of a subject by administering to the subject a composition for stimulating melanogenesis comprising Cirsium japonicum extract as an active ingredient.
- The composition administered to the subject has an effect of improving or treating vitiligo, white hair and hypopigmentation of the subject due to the melanin production promoting effect as described above.
- The term, “subject” in the present invention means a mammal such as monkey, cow, horse, pig, sheep, dog, cat, rat, mouse, chimpanzee, etc., including human, having the disease symptom of which can be alleviated by administering the composition of the present invention.
- In the present invention, the term “improvement” means (a) inhibition of a development, (b) alleviation and (c) removal of the vitiligo, white hair and hypopigmentation resulting from disruption or dysfunction of melanocytes in a subject.
- On the other hand, Cirsium japonicum extract of the present invention is a natural extract that has no skin irritation and cytotoxicity and excellent human stability and has almost no side effects on the human body, and thus is very effective in stimulating melanogenesis. It can be safely used as an active ingredient in therapeutic cosmetics or pharmaceutical compositions.
- In another specific embodiment, the present invention provides a method for preventing, improving, or treating vitiligo, white hair or hypopigmentation by promoting the production of melanin by administering to a subject a composition comprising the Cirsium japonicum extract as an active ingredient.
- The subject is a mammal, including humans, which is intended to improve vitiligo, white hair or hypopigmentation by stimulating melanogenesis.
- The administration is oral or parenteral administration, preferably parenteral administration, more preferably topical administration by application. The dosage and the like can be easily changed and used by those skilled in the art the method of formulation, mode of administration, age, weight, sex of a patient, morbidity, etc.
- By administering to the subject a composition for the prevention, improvement or treatment of vitiligo, white hair or hypopigmentation according to the present invention, the melanin production of the subject may be promoted to prevent and improve vitiligo, white hair or hypopigmentation.
- The composition for stimulating melanogenesis comprising Cirsium japonicum extract as an effective ingredient has no skin irritation and cytotoxicity and is excellent in human stability and very effective in stimulating melanogenesis. Therefore, the composition can be safely used in cosmetic or pharmaceutical composition for preventing, improving or treating vitiligo, white hair or hypopigmentation.
-
FIG. 1 shows the melanin synthesis promoting effect depending on the concentration of Cirsium japonicum extract in human melanocyte. -
FIG. 2 shows the melanin synthesis promoting effect depending on the concentration of Cirsium japonicum extract in B16 melanoma cell. -
FIG. 3 shows the melanin synthesis promoting effect depending on the concentration of Cirsium japonicum extract in 3D skin. - In order to achieve the above object, the present invention provides a composition for stimulating melanogenesis comprising Cirsium japonicum extract as an active ingredient.
- In order to achieve the above another object, the present invention provides a cosmetic composition for preventing or improving vitiligo, white hair or hypopigmentation, characterized in that it comprises Cirsium japonicum extract as an active ingredient.
- In order to achieve the above another object, the present invention provides a pharmaceutical composition for preventing or treating vitiligo, white hair or hypopigmentation, characterized in that it comprises Cirsium japonicum extract as an active ingredient.
- In order to achieve the above another object, the present invention provides a method for preventing, improving or treating vitiligo, white hair or hypopigmentation by promoting the melanin production by administering to the subject a composition comprising the Cirsium japonicum extract as an active ingredient.
- Hereinafter, the present invention will be given in detail through Examples. The Examples is given only to more specifically describe the present invention, and it will be self-evident to the ordinary person in the art to which the present invention subject that the scope of the present invention is not limited to such Examples.
- Cirsium japonicum flowers were harvested and washed thoroughly to remove any foreign matter and impurities. It was dried at 20 to 35° C. and then ground to a particle size of 1 mm or less. Thereafter, 1 kg of the Cirsium japonicum flower powder was soaked in 70% ethanol solvent, sonicated for 48 hours, and the obtained extract was filtered using filter paper (Advantes, No. 2). The filtrate was concentrated under reduced pressure to prepare Cirsium japonicum extract.
- Human melanocytes were inoculated into 6-well plate containing M254 medium with HMGS (Human Melanocytes Growth Supplement) at a density 1.5×105 cells per well, and then cultured in 5% concentration of CO2 cultivator under the condition of 37° C. until at least about 80% adhered to the bottom of the well. Thereafter, the medium was removed and the sample of Example 1 was replaced with a medium diluted to an appropriate concentration, and then incubated in 5% concentration of CO2 under the condition of 37° C. for 5 days. The concentration range of Cirsium japonicum extract according to Example 1 was determined to be 1 ppm, 3 ppm, 5 ppm without cytotoxicity. The cells from which the medium was removed were washed with PBS (phosphated buffer saline), and the cells were obtained. The obtained cells were counted using a hemocytometer and then centrifuged at 10,000 to 13,000 rpm for 10 minutes to remove the supernatant and pellets were obtained. The obtained cell pellet was dried at 60° C., and then 100 μl of 1M sodium hydroxide solution containing 10% DMSO was added to obtain an intracellular melanin solution in a 60° C. thermostat. Using this solution, the absorbance at 450 nm was measured with a microplate reader to determine the amount of melanin per cell. The results are shown in Table 1 and
FIG. 1 . -
TABLE 1 Treatment Melanin production Sample concentration (ppm) promotion ratio (%) Control — 100 Cirsium japonicum 1 110 extract 3 116 5 122 - As shown in Table 1 and
FIG. 1 , Cirsium japonicum extract according to the present invention was observed to increase the rate of melanin production in a concentration-dependent compared to the control. Therefore, Cirsium japonicum extract according to the present invention was found to have the effect of promoting the production of melanin. - B16 melanoma cells were inoculated into 6-well plate containing DMEM medium with 10% FBS (Fetal Bovine Serum) at a density 1.5×105 cells per well, and then cultured in 5% concentration of CO2 cultivator under the condition of 37° C. until at least about 80% adhered to the bottom of the well. Thereafter, the medium was removed and the sample of Example 1 was replaced with a medium diluted to an appropriate concentration, and then incubated in 5% concentration of CO2 under the condition of 37° C. for 3 days. The concentration range of Cirsium japonicum extract according to Example 1 was determined to be 10 ppm, 50 ppm, 100 ppm without cytotoxicity. The cells from which the medium was removed were washed with PBS (phosphated buffer saline), and the cells were obtained. The obtained cells were counted using a hemocytometer and then centrifuged at 10,000 to 13,000 rpm for 10 minutes to remove the supernatant and pellets were obtained. The obtained cell pellet was dried at 60° C., and then 100 μl of 1M sodium hydroxide solution containing 10% DMSO was added to obtain an intracellular melanin solution in a 60° C. thermostat. Using this solution, the absorbance at 450 nm was measured with a microplate reader to determine the amount of melanin per cell. The results are shown in Table 2 and
FIG. 2 . -
TABLE 2 Treatment Melanin production Sample concentration (ppm) promotion ratio (%) Control — 100 Cirsium japonicum 10 111 extract 50 159 100 222 - As shown in Table 2 and
FIG. 2 , Cirsium japonicum extract according to the present invention was observed to increase the rate of melanin production in a concentration-dependent compared to the control. When Cirsium japonicum extract was treated with 100 ppm, it was observed that the melanin production was promoted more than two times compared to the control. Therefore, Cirsium japonicum extract according to the present invention was found to have the effect of promoting the production of melanin. - 3D skin were inoculated into 6-well plate containing maintenance medium, and then cultured in 5% concentration of CO2 cultivator under the condition of 37° C. Thereafter, the medium was removed, and the Cirsium japonicum extracts were treated at ppm and 100 ppm without cytotoxicity. Cirsium japonicum extract was replaced three times with a concentration-treated medium for 10 days and then incubated at 5% CO2 and 37° C. The cells from which the medium was removed were washed with PBS (phosphated buffer saline), and the cells were obtained. The obtained cells were centrifuged at 10,000 to 13,000 rpm for 10 minutes to remove the supernatant and pellets were obtained. The obtained cell pellet was dried at 60° C., and then 100 μl of 1M sodium hydroxide solution containing 10% DMSO was added to obtain an intracellular melanin solution in a 60° C. thermostat. Using this solution, the absorbance at 450 nm was measured with a microplate reader to determine the amount of melanin per cell. The results are shown in Table 3 and
FIG. 3 . -
TABLE 3 Treatment Melanin production Sample concentration (ppm) promotion ratio (%) Control — 100 Cirsium japonicum 50 120 extract 100 128 - As shown in Table 3 and
FIG. 3 , Cirsium japonicum extract according to the present invention was observed to increase the rate of melanin production in a concentration-dependent compared to the control. Therefore, Cirsium japonicum extract according to the present invention was found to have the effect of promoting the production of melanin. - In order to identify as to whether the Cirsium japonicum extract is safe or not, a test for identifying the safety to the human skin was performed. For this, a cumulative skin irritation was carried out.
- A nutritious cream containing 0.1%, 0.5% and 1% of Cirsium japonicum extracts of Example 1, respectively, was prepared. Specifically, purified water, triethanolamine, and propylene glycol were heated and dissolved at a temperature of 70° C. (aqueous phase). Beeswax, liquid paraffin, oily ingredients, emulsifiers and preservatives were heated and dissolved at a temperature of 70° C. (oil phase). The oil phase was added to the aqueous phase to prepare an emulsion. After emulsification was completed, the solution was cooled to 45° C., and Cirsium japonicum extracts were added 0.1%, 0.5% and 1% respectively, dispersed and then cooled to 30° C. As the content of the Cirsium japonicum extract was increased to 0.1%, 0.5% and 1%, the nutritional cream was prepared by reducing the content of the liquid paraffin to 9.91%, 9.51% and 9.01%, respectively.
- The nourishing cream prepared as described above was applied as a patch to areas of humerus of 30 adults for accumulated 24 hours on alternate day in total 9 times to test as to whether the Cirsium japonicum extract stimulates the skin.
- The patch used Finn chamber (Epitest Ltd, Filand) and the patch was practiced after dropping with 15 μl of the skin external preparations prepared from the above, respectively. The degree of the reaction represented on the skin in every time was scored by using the below experimental formula 1. The results are represented in Table 4.
-
Mean reaction degree=[{(reaction index×reaction degree)/(total number of the subject×the highest score (four point))}×100]/times of the test (9 times) [Experimental Formula 1] - In regard to the response degree, 1 point was provided for ±, 2 points for +, and 4 points for ++. When the mean reaction degree is less than 3, it is considered as being the safe composition.
-
TABLE 4 Number of subjects showing response 1st week 2nd week 3rd week Average Test 1st 2nd 3rd 4th 5th 6th 7th 8th 9th response material ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ ± + ++ degree Control group 1 − − 0 − − − − − − − − − − − − − − − − − − − − − − − 0.09 (Squalene) Cirsium 0 − − 0 − − − − − − − − − − − − − − − − − − − − − − − 0.00 japonicum extract (0.1%) [Test group 1] Cirsium 0 − − 0 − − − − − − − − − − − − − − − − − − − − − − − 0.00 japonicum extract (0.5%) [Test group 2] Cirsium 0 − − 0 − − − − − − − − − − − − − − − − − − − − − − − 0.00 japonicum extract (1%) [Test group 3] - As shown in the above Table 4, in all of the test groups 1, 2, and 3, all numbers of subjects belonging to ±, +, ++ were 0 and Average response degree was also 0.00. As a result of the above test, test group are all less than 3, and thus, it was determined that the Cirsium japonicum extract is safe for use on human skin which does not show clear cumulative skin irritation.
- The composition of the present invention may be prepared as an example as follows but is not limited thereto.
- 1-1. Preparation of Softening Toner
- Shown in Table 5 below, a softening toner containing the Cirsium japonicum extract as an active ingredient was prepared according to a conventional method.
-
TABLE 5 Component Content (wt %) Cirsium japonicum extract 0.01 Glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 Ethanol 10.0 Triethanolamine 0.1 Preservative, trace amount of pigment, 82.79 trace amount of fragrance, and trace amount of purified water Total 100.0 - 1-2. Preparation of Nourishing Toner
- Shown in Table 6 below, a nourishing toner containing the Cirsium japonicum extract as an active ingredient was prepared according to a conventional method.
-
TABLE 6 Component Content (wt %) Cirsium japonicum extract 0.01 Beeswax 4.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 5.0 Squalane 5.0 caprylic/capric triglyceride 5.0 Glycerin 3.0 Butylene glycol 3.0 Propylene glycol 3.0 Carboxyvinyl polymer 0.1 Triethanolamine 0.2 Preservative, trace amount of pigment, 69.69 trace amount of fragrance, and trace amount of purified water Total 100.0 - 1-3. Preparation of Nourishing Cream
- Shown in Table 7 below, a nourishing cream containing the Cirsium japonicum extract as an active ingredient was prepared according to a conventional method.
-
TABLE 7 Component Content (wt %) Cirsium japonicum extract 0.01 Beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.5 Liquid paraffin 10.0 Squalane 5.0 caprylic/capric triglyceride 5.0 Glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, trace amount of pigment, 56.79 trace amount of fragrance, and trace amount of purified water Total 100.0 - 1-4. Preparation of Massage Cream
- Shown in Table 8 below, a massage cream containing the Cirsium japonicum extract as an active ingredient was prepared according to a conventional method.
-
TABLE 8 Component Content (wt %) Cirsium japonicum extract 0.01 Beeswax 10.0 Polysorbate 60 1.5 Sorbitan sesquioleate 0.8 Liquid paraffin 40.0 Squalane 5.0 caprylic/capric triglyceride 4.0 Glycerin 5.0 Butylene glycol 3.0 Propylene glycol 3.0 Triethanolamine 0.2 Preservative, trace amount of pigment, 27.49 trace amount of fragrance, and trace amount of purified water Total 100.0 - 1-5: Preparation of Pack
- Shown in Table 9 below, a pack containing the Cirsium japonicum extract as an active ingredient was prepared according to a conventional method.
-
TABLE 9 Component Content (wt %) Cirsium japonicum extract 0.01 Polyvinyl alcohol 13.0 Sodium carboxymethyl cellulose 0.2 Allantoin 0.1 Ethanol 5.0 Nonyl phenyl ether 0.3 Preservative, trace amount of pigment, Balance trace amount of fragrance, and trace amount of purified water Total 100.0 - 2-1. Preparation of Powder Formulation
-
TABLE 10 Component Content (g) Cirsium japonicum extract 2 Lactose 1 - The above components were mixed with each other and then filled in a sealed bag, thereby preparing a powder formulation containing Cirsium japonicum extract as an active ingredient.
- 2-2: Preparation of Tablet Formulation
-
TABLE 11 Component Content (mg) Cirsium japonicum extract 100 Corn starch 100 Lactose 100 Magnesium stearate 2 - The above components were mixed with each other and then compressed to a tablet according to a conventional method, thereby preparing a tablet formulation containing Cirsium japonicum extract as an active ingredient.
- 2-3: Preparation of Capsule Formulation
-
TABLE 12 Component Content (mg) Cirsium japonicum extract 100 Corn starch 100 Lactose 100 Magnesium stearate 2 - The above components were mixed with each other and then filled into a gelatin capsule according to a conventional method, thereby preparing a capsule formulation containing Cirsium japonicum extract as an active ingredient.
- The composition for stimulating melanogenesis comprising Cirsium japonicum extract as an effective ingredient has no skin irritation and cytotoxicity and is excellent in human stability and very effective in stimulating melanogenesis. Therefore, the composition can be safely used in cosmetic or pharmaceutical composition for preventing, improving or treating vitiligo, white hair or hypopigmentation.
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2017-0035571 | 2017-03-21 | ||
KR1020170035571A KR101989407B1 (en) | 2017-03-21 | 2017-03-21 | A composition for promoting melanin synthesis comprising Cirsium japonicum extract |
PCT/KR2018/002898 WO2018174453A1 (en) | 2017-03-21 | 2018-03-12 | Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2018/002898 A-371-Of-International WO2018174453A1 (en) | 2017-03-21 | 2018-03-12 | Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/831,558 Division US12303588B2 (en) | 2017-03-21 | 2022-06-03 | Composition containing Cirsium japonicum extract as active ingredient for stimulating melanogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210361559A1 true US20210361559A1 (en) | 2021-11-25 |
Family
ID=63584627
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/496,565 Abandoned US20210361559A1 (en) | 2017-03-21 | 2018-03-12 | Composition containing cirsium japonicum extract as active ingredient for stimulating melanogenesis |
US17/831,558 Active 2039-05-27 US12303588B2 (en) | 2017-03-21 | 2022-06-03 | Composition containing Cirsium japonicum extract as active ingredient for stimulating melanogenesis |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/831,558 Active 2039-05-27 US12303588B2 (en) | 2017-03-21 | 2022-06-03 | Composition containing Cirsium japonicum extract as active ingredient for stimulating melanogenesis |
Country Status (6)
Country | Link |
---|---|
US (2) | US20210361559A1 (en) |
EP (1) | EP3643295A4 (en) |
JP (1) | JP6921440B2 (en) |
KR (1) | KR101989407B1 (en) |
CN (1) | CN110650724A (en) |
WO (1) | WO2018174453A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101989407B1 (en) | 2017-03-21 | 2019-06-14 | 바이오스펙트럼 주식회사 | A composition for promoting melanin synthesis comprising Cirsium japonicum extract |
KR102110903B1 (en) * | 2018-11-28 | 2020-05-19 | 바이오스펙트럼 주식회사 | A composition for promoting melanin synthesis comprising flower extract of Cirsium genus |
KR102142930B1 (en) * | 2018-11-28 | 2020-08-11 | 바이오스펙트럼 주식회사 | A composition for promoting melanin synthesis comprising flower extract of milk thistle |
KR102249072B1 (en) * | 2019-07-11 | 2021-05-06 | 인하대학교 산학협력단 | Pharmaceutical composition for preventing or treating vitiligo or canities comprising extract of Cichorium intybus as an active ingredient |
KR102588837B1 (en) * | 2020-12-03 | 2023-10-12 | 제주대학교 산학협력단 | A composition for promoting melanin synthesis comprising linarin |
EP4144345A1 (en) | 2021-09-06 | 2023-03-08 | Clariant International Ltd | Prunella vulgaris extract and use thereof |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5698199A (en) * | 1995-03-10 | 1997-12-16 | Kao Corporation | Lipolysis acceleration method |
JP3526985B2 (en) * | 1995-10-09 | 2004-05-17 | 花王株式会社 | Bath composition |
JP2001131026A (en) * | 1999-11-08 | 2001-05-15 | Shiseido Co Ltd | Cosmetic for scalp and hair |
KR20020050261A (en) | 1999-11-08 | 2002-06-26 | 겜마 아키라 | Scalp and hair care compositions |
JP2001131032A (en) | 1999-11-08 | 2001-05-15 | Shiseido Co Ltd | Cosmetic for scalp and hair |
JP2003171240A (en) * | 2001-09-28 | 2003-06-17 | Lion Corp | Method for preventing and improving gray hair and method for screening active ingredients for hair |
FR2834718B1 (en) | 2002-01-15 | 2004-12-24 | Cognis France Sa | COSMETIC AND / OR PHARMACEUTICAL ACTIVE SUBSTANCES |
FR2881953A1 (en) * | 2005-02-11 | 2006-08-18 | Greenpharma Sa Sa | USE OF TAXIFOLINE DERIVATIVES AS PIGMENTANTS AND PROTECTIVE AGENTS FOR SKIN OR HAIR |
KR100728813B1 (en) * | 2005-08-18 | 2007-06-19 | 한불화장품주식회사 | Skin external composition containing Korean thistle extract as main active ingredient |
KR20080102939A (en) * | 2007-11-09 | 2008-11-26 | 한국생명공학연구원 | Skin whitening composition containing silibine or isosilbin as an active ingredient |
US9445987B2 (en) * | 2009-10-05 | 2016-09-20 | Kao Corporation | Ceramide production enhancer and moisturizer |
KR101281710B1 (en) | 2010-03-11 | 2013-07-26 | 건국대학교 산학협력단 | Composition comprising an extact of cirsium japonicum and the compounds isolated thereform for the treatment and preventation of obesity |
JP5036897B1 (en) | 2011-09-10 | 2012-09-26 | 株式会社ビティー | Kitchen facilities partitioned by a bar counter |
JP5951273B2 (en) * | 2012-02-08 | 2016-07-13 | 三省製薬株式会社 | Topical agent for preventing white hair |
KR101669359B1 (en) | 2015-03-11 | 2016-10-26 | 경상대학교산학협력단 | composition for promoting melanin synthesis |
KR20170025375A (en) * | 2015-08-28 | 2017-03-08 | 주식회사 엘지생활건강 | Composition for improving skin |
CN105434764A (en) * | 2015-12-18 | 2016-03-30 | 高松武 | Traditional Chinese medicine capsules for treating vitiligo |
CN106421150A (en) * | 2016-10-19 | 2017-02-22 | 罗锡山 | Guangxi Zhuang medicine for treating leucoderma |
KR101989407B1 (en) | 2017-03-21 | 2019-06-14 | 바이오스펙트럼 주식회사 | A composition for promoting melanin synthesis comprising Cirsium japonicum extract |
CN108785155A (en) * | 2017-04-28 | 2018-11-13 | 捷通国际有限公司 | Composition and correlation technique for treating cutaneous pigmentation |
-
2017
- 2017-03-21 KR KR1020170035571A patent/KR101989407B1/en active Active
-
2018
- 2018-03-12 US US16/496,565 patent/US20210361559A1/en not_active Abandoned
- 2018-03-12 JP JP2019552221A patent/JP6921440B2/en active Active
- 2018-03-12 WO PCT/KR2018/002898 patent/WO2018174453A1/en unknown
- 2018-03-12 CN CN201880033218.3A patent/CN110650724A/en active Pending
- 2018-03-12 EP EP18770560.3A patent/EP3643295A4/en active Pending
-
2022
- 2022-06-03 US US17/831,558 patent/US12303588B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3643295A4 (en) | 2020-12-30 |
US20220287956A1 (en) | 2022-09-15 |
KR20180106755A (en) | 2018-10-01 |
JP6921440B2 (en) | 2021-08-18 |
WO2018174453A1 (en) | 2018-09-27 |
KR101989407B1 (en) | 2019-06-14 |
JP2020511514A (en) | 2020-04-16 |
US12303588B2 (en) | 2025-05-20 |
EP3643295A1 (en) | 2020-04-29 |
CN110650724A (en) | 2020-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12303588B2 (en) | Composition containing Cirsium japonicum extract as active ingredient for stimulating melanogenesis | |
US8802164B2 (en) | Method for promoting carnitine palmitoyltransferase activity using green coffee bean extract | |
KR102142930B1 (en) | A composition for promoting melanin synthesis comprising flower extract of milk thistle | |
KR20100010316A (en) | Cosmetic composition for preventing skin aging | |
KR20090130584A (en) | Cosmetic composition for skin whitening and wrinkle improvement containing complex herbal extract as an active ingredient | |
KR20130032421A (en) | Composition for the improvement of leukoderma using an extract of chrysanthemum indicum | |
KR102626479B1 (en) | Gentiana extract without gentiopicroside | |
KR101065356B1 (en) | Camellia gourd (camellia seed shell powder) and its use | |
KR102127771B1 (en) | A composition for antioxidation, anti-inflammation, antiaging or skin soothing comprising herb complex extracts | |
KR101367703B1 (en) | Composition of cosmetic and treating skin disease | |
KR101419587B1 (en) | Composition for Promoting Regeneration of Skin Comprising Ginseng Oil as Active Ingredient | |
KR102386120B1 (en) | Composition for preventing hair loss or promoting hair growth comprising milk thistle flower extract as an active ingredient | |
KR102110903B1 (en) | A composition for promoting melanin synthesis comprising flower extract of Cirsium genus | |
KR20140114709A (en) | Composition for Improving Skin Conditions Comprising Boehmeria spicata (Thunb.) Thunb Extract | |
KR20180050798A (en) | Cosmetic compositions containing Zingiberaceae extracts for skin homeostasis and nontoxicity and manufacturing method thereof | |
KR102831785B1 (en) | Composition for Promoting Melanin synthesis comprising Sargassum fusiforme extract | |
KR101743001B1 (en) | Cosmetic composition containing chitosan and propolis extracts | |
KR102780317B1 (en) | Compositions for inhibiting sebum secretion comprising Sargassum fusiforme extracts | |
KR102840764B1 (en) | Composition for Promoting Melanin synthesis comprising Smilax china extract | |
KR102718114B1 (en) | Composition for inhibiting body odor, serum secretion, and dandruff comprising Lagerstroemia indica extracts as an active ingredient | |
KR101222673B1 (en) | The cosmetic composition for scalp-calming and alleviating skin irritation containing the extract of eclipta prostrate, symphytum officinale, platycodon grandiflorum, and theobroma cacao | |
KR102780319B1 (en) | Composition for improving hair scalp comprising Camellia japonica pericarp extract as an active ingredient | |
KR101072725B1 (en) | Composition containing as available ingredient the extracts of Bupleurum falcatum L. | |
KR101832862B1 (en) | Compositions containing an extract of phlomis korainensis nakai for skin whitening | |
KR100808418B1 (en) | Cosmetic composition containing sunscreen, cinnamon, oil, lotus, geranium extract having skin astringent effect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOSPECTRUM, INC., KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KIM, MIN KYUNG;SON, DA HEE;SHIN, SEOUNG WOO;AND OTHERS;REEL/FRAME:050459/0480 Effective date: 20190920 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |